BiotechTube
EverImmune

EverImmune

Paris, France· Est.
everimmune.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.7M

Overview

EverImmune is a clinical-stage biotech developing a novel class of cancer treatments based on the gut microbiome. The company's core technology involves identifying and formulating specific bacterial strains or consortia, branded as Oncobax®, which are designed to convert 'cold' tumors responsive to immunotherapy into 'hot' ones. Its lead candidate, Oncobax® AM, is a specific strain of Akkermansia muciniphila being prepared for a Phase 2 trial in non-small cell lung cancer (NSCLC) patients resistant to immunotherapy. EverImmune operates as a private, pre-revenue company advancing a pipeline of live biotherapeutic products through strategic research and planned clinical trials.

Oncology

Technology Platform

Platform for identifying and formulating specific bacterial strains or consortia (live biotherapeutic products - LBPs) designed to modulate the gut microbiome and overcome resistance to cancer immunotherapy.

Funding History

2
Total raised:$10.7M
Series A$8M
Seed$2.7M

Opportunities

The company targets the large and growing market of cancer patients who do not respond to immunotherapy, a multi-billion dollar unmet need.
Success with its lead candidate in NSCLC could validate its platform for expansion into numerous other immunotherapy-treated cancers.
The evolving regulatory pathway for live biotherapeutics and strong scientific interest in the microbiome-oncology axis create a favorable environment for breakthrough therapies.

Risk Factors

High clinical risk as the novel mechanism of using single bacterial strains to overcome immunotherapy resistance is unproven in late-stage trials.
The company faces significant competition from other microbiome-focused biotechs and depends on continued financing to advance its costly clinical programs.
Regulatory hurdles for novel live biotherapeutic products are substantial and evolving.

Competitive Landscape

EverImmune operates in the competitive microbiome-oncology space, competing with companies like Seres Therapeutics, Vedanta Biosciences, and MaaT Pharma, which are developing bacterial consortia or FMT-based therapies. It differentiates by focusing on specific, single-strain candidates like Akkermansia muciniphila. Larger pharma companies are also active in the space through partnerships and internal research, making it a dynamic and fast-moving field.

More companies in Microbiome Therapeutics →More companies in France →